Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. Growing adoption of biologics
4.1.1.2. Increasing R&D on regenerative medicines
4.1.2. Restraints:
4.1.2.1. Side effects associated with gout therapeutics
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Regulatory Analysis
5.3. Supply Chain Analysis
5.4. Pricing Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Epidemiology
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
7.1.2. Market Attractiveness Index, By Drug Class Segment
7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.2.3. Ibuprofen
7.2.4. Naproxen
7.2.5. Indomethacin
7.2.6. Celecoxib
7.2.7. Others
7.3. Anti-hyperuricemic Agents (Urate-Lowering Drugs)
7.3.1. Xanthine oxidase inhibitors
7.3.1.1. Allopurinol (Lopurin, Zyloprim)
7.3.1.2. Febuxostat (Uloric)
7.3.2. Uricosuric Medications
7.3.2.1. Benzbromarone
7.3.2.2. Probenecid
7.3.2.3. Sulfinpyrazone
7.3.3. Uricases
7.3.3.1. Pegloticase
7.3.3.2. Rasburicase
7.4. Corticosteroids
7.4.1. Dexamethasone (DexPak)
7.4.2. Methylprednisolone (Medrol)
7.4.3. Prednisolone (Omnipred)
7.4.4. Prednisone (Rayos)
7.4.5. Triamcinolone (Aristospan)
7.5. Colchicine
7.5.1. Colcrys
7.5.2. Mitigare
7.6. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
8.1.2. Market Attractiveness Index, By Application Segment
8.2. Acute Gout
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Chronic Gout
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
9.1.2. Market Attractiveness Index, By End User Segment
9.2. Hospital Pharmacies
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Drug Stores
9.4. Online Channels
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Drug Class Benchmarking
11.4. List of Key Companies to Watch
12. Company Profiles
12.1. Novartis International AG
12.1.1. Company Overview
12.1.2. Drug Class Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. GlaxoSmithKline PLC
12.3. Lannett Company, Inc
12.4. Mylan NV
12.5. Boehringer Ingelheim
12.6. Horizon Therapeutics plc
12.7. Regeneron Pharmaceuticals
12.8. Takeda Pharmaceutical Company Ltd
12.9. Teijin Pharma Ltd
12.10. Romeg Therapeutics, LLC
LIST NOT EXHAUSTIVE
13. Global Gout Therapeutics Market – DataM
13.1. Appendix
13.2. About Us and Application
13.3. Contact Us